The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:2088-2089 November 10, 2005 Number 19
NextNext

Post-Transplantation Proteinuria and Sirolimus

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Proteinuria may develop in renal-transplant recipients who have converted from treatment with calcineurin inhibitors to treatment with sirolimus1; the mechanism of this occurrence is unknown. We hypothesized that the antiangiogenic properties of sirolimus might be responsible. We determined the plasma concentrations and renal expression of vascular endothelial growth factor (VEGF) in a specimen from a renal-allograft biopsy performed to evaluate post-transplantation proteinuria during sirolimus conversion in a patient with Kaposi's syndrome.

A 68-year-old man with alcoholic cirrhosis and end-stage renal disease due to IgA nephropathy underwent cadaveric liver and renal transplantation in May 1996. Eight years . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.